JP2020518604A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518604A5
JP2020518604A5 JP2019560115A JP2019560115A JP2020518604A5 JP 2020518604 A5 JP2020518604 A5 JP 2020518604A5 JP 2019560115 A JP2019560115 A JP 2019560115A JP 2019560115 A JP2019560115 A JP 2019560115A JP 2020518604 A5 JP2020518604 A5 JP 2020518604A5
Authority
JP
Japan
Prior art keywords
seq
immunoglobulin
patient
ige
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019560115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518604A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/053106 external-priority patent/WO2018203289A1/en
Publication of JP2020518604A publication Critical patent/JP2020518604A/ja
Publication of JP2020518604A5 publication Critical patent/JP2020518604A5/ja
Pending legal-status Critical Current

Links

JP2019560115A 2017-05-05 2018-05-04 Ｉｌ−１７アンタゴニストを使用して喘息を選択的に治療する方法 Pending JP2020518604A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762501806P 2017-05-05 2017-05-05
US62/501,806 2017-05-05
PCT/IB2018/053106 WO2018203289A1 (en) 2017-05-05 2018-05-04 Methods of selectively treating asthma using il-17 antagonists

Publications (2)

Publication Number Publication Date
JP2020518604A JP2020518604A (ja) 2020-06-25
JP2020518604A5 true JP2020518604A5 (enExample) 2020-09-24

Family

ID=62245372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019560115A Pending JP2020518604A (ja) 2017-05-05 2018-05-04 Ｉｌ−１７アンタゴニストを使用して喘息を選択的に治療する方法

Country Status (13)

Country Link
US (1) US10676522B2 (enExample)
EP (1) EP3619536A1 (enExample)
JP (1) JP2020518604A (enExample)
KR (1) KR20190142398A (enExample)
CN (1) CN110582702A (enExample)
AU (1) AU2018263159A1 (enExample)
BR (1) BR112019023141A2 (enExample)
CA (1) CA3062179A1 (enExample)
CL (1) CL2019003161A1 (enExample)
MX (1) MX2019013160A (enExample)
RU (1) RU2019139387A (enExample)
TW (1) TW201842933A (enExample)
WO (1) WO2018203289A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689907A1 (en) * 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
JP2023521909A (ja) * 2020-04-17 2023-05-25 イーライ リリー アンド カンパニー 呼吸器疾患の治療

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308324D0 (en) 2003-04-10 2003-05-14 Piezoptic Ltd A chemical sensing device
CN1898564A (zh) * 2003-12-24 2007-01-17 惠氏公司 治疗哮喘的方法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
HUE039353T2 (hu) 2005-12-13 2018-12-28 Lilly Co Eli Anti-IL-17 ellenanyagok
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US20110123530A1 (en) * 2008-03-31 2011-05-26 Arron Joseph R Compositions and methods for treating and diagnosing asthma
RU2539029C2 (ru) 2008-09-29 2015-01-10 Роше Гликарт Аг Антитела против интерлейкина 17 (ил-17) человека и их применение
CA2897682C (en) 2013-02-08 2023-03-14 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
AU2014340129A1 (en) * 2013-10-23 2016-05-26 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
US20160000936A1 (en) * 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
FI3191120T3 (fi) * 2014-09-10 2024-07-10 Novartis Ag Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla
GB201508832D0 (en) 2015-05-22 2015-07-01 Novartis Ag A method for detecting an analyte

Similar Documents

Publication Publication Date Title
US12044681B2 (en) Protein signatures for distinguishing between bacterial and viral infections
Laing et al. A dynamic COVID-19 immune signature includes associations with poor prognosis
EP3482201B1 (en) Early diagnosis of infections
EP4033248B1 (en) System and method for analysis of mx1 and crp in blood
CN105980856A (zh) 用于早期确定对疾病的危象反应或威胁生命反应和/或治疗反应的生物标志物
EP3475702A1 (en) Measuring trail by lateral flow immunoassay
CN113474657B (zh) 使用微粒去除非特异性结合信号的方法
CN113791212B (zh) 新型冠状病毒中和抗体磁珠荧光检测试剂盒及其检测方法
Pohanka et al. Diagnosis of tularemia using piezoelectric biosensor technology
Jalali et al. Aptamer based diagnosis of crimean-congo hemorrhagic fever from clinical specimens
JP2020518604A5 (enExample)
JP2007502837A5 (enExample)
JP2019526231A (ja) 二本鎖核酸信号プローブおよびこれを用いた標的分子の検出方法
WO2023034933A1 (en) Methods and systems for assessing adaptive immunity to coronavirus
RU2019139387A (ru) Способы селективного лечения астмы с использованием антагонистов il-17
JP2019032317A5 (enExample)
Grace et al. Latex agglutination test for rapid on-site serodiagnosis of Japanese encephalitis in pigs using recombinant NS1 antigen
Huang et al. Establishment of a bead‐based duplex assay for the simultaneous quantitative detection of Neuropilin‐1 and Neuropilin‐2 using xMAP technology and its clinical application
CN103045600B (zh) 结核患者血清IgG抗体适配子及其制备方法
US20200284799A1 (en) Rapid test for cellular fibronectin
Nguyen Correlation between immune system activity and the susceptibility to Long COVID symptoms
Kim et al. Journal of Advanc ed Research
JP5010220B2 (ja) 造血幹細胞移植療法の施行患者の病態把握方法
WO2017066538A1 (en) Combination of serotonin and a cytokine as an early, prognostic predictor of severe dengue
Masson et al. and Dried Blood Spots with Filter Paper Sampling Techniques and Dilutions of the Lymphatic Filariasis Og4C3 Antigen ELISA for Samples from Myanmar